Fidelity Investments
SGMT icon

Fidelity Investments’s Sagimet Biosciences SGMT Stock Holding History

Fidelity Investments’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$774 Buy
148
+15
+11% +$84 ﹤0.01% 5120
2025
Q4 		$788 Sell
133
-46
-26% -$331 ﹤0.01% 5119
2025
Q3 		$1.23K Buy
179
+120
+203% +$973 ﹤0.01% 4995
2025
Q2 		$447 Buy
59
+11
+23% +$46 ﹤0.01% 5042
2025
Q1 		$156 Hold
48
– – ﹤0.01% 5093
2024
Q4 		$216 Hold
48
– – ﹤0.01% 5051
2024
Q3 		$133 Sell
48
-1,342
-97% -$4.14K ﹤0.01% 5064
2024
Q2 		$4.75K Sell
1,390
-129,606
-99% -$595K ﹤0.01% 4561
2024
Q1 		$710K Sell
130,996
-1,791,060
-93% -$12.9M ﹤0.01% 2603
2023
Q4 		$10.4M Sell
1,922,056
-750,299
-28% -$3.54M ﹤0.01% 1836
2023
Q3 		$23.5M Buy
+2,672,355
New +$35.6M ﹤0.01% 1528

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fidelity Investments's SGMT Position: Q1 2026 in Review

Fidelity Investments increased its Sagimet Biosciences (SGMT) stake by 11% in Q1 2026, buying an estimated $84 and bringing the position to 148 shares worth $774. The position accounts for ﹤0.01% of the portfolio, ranked #5120.

Fidelity Investments first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $23.5M in Q3 2023. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Fidelity Investments held 148 shares of Sagimet Biosciences worth $774 as of Q1 2026.
  • Fidelity Investments bought 15 Sagimet Biosciences shares in Q1 2026, an estimated $84.
  • Sagimet Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5120 holding.
  • Fidelity Investments first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Fidelity Investments's Sagimet Biosciences position peaked at $23.5M in Q3 2023.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.